Sequencing the genome is one thing. Making sense of the data that generates is another.
That’s what Syapse Inc., self-proclaimed as “one of the largest repositories of human molecular profiles,” is helping laboratories and sequencing companies do with its biomedical data platform that aggregates and structures data from separate warehouses including sequencers.
The latest victory for the Palo Alto, California-based startup is closing a $3 million series A round led by The Social+Capital Partnership, a venture fund launched by former Facebook Vice President Chamath Palihapitiya. In its two years of existence, the partnership has invested in tech companies including Yammer, SurveyMonkey and Flatiron Health, according to CrunchBase.
For Syapse, the round follows a previously unannounced $1.5 million seed round.
Syapse’s cloud-based Discovery platform, launched last summer, is used primarily by diagnostic laboratories and sequencing platform companies. “Diagnostic laboratoriesuse Discovery to track the laboratory work flow they go through and the data generated, the analysis process after sequencing, and the omics results generated,” said co-founder and President Jonathan Hirsch in an email. “All of this information can then be combined together and used to conduct research, optimize processes and generate a report for the physician, which Syapse software will electronically deliver.”
Similarly, a sequencing platform company would use it to track processes, work flows and metrics to optimize the development of its sequencer. Once the sequencer is developed, the company can connect it to Syapse’s data platform via the cloud, so the data flows directly there.
Syapse says its software is compatible with all major sequencers and is now involved in the processing of more than 3,000 patient genomes per quarter. The startup has acquired customers like Foundation Medicine and Genapsys.
Hirsch said a second application, which would serve as an “omics medical record” to assist healthcare providers in using omics in the diagnosis and treatment of patients, is currently in private beta.
Hirsch, who got his start working at Abbott Laboratories, founded the company in 2008 at Stanford University along with software engineer Tony Loeser and software industry executive and investor Glenn Winokur.